Or. Admin. Code § 855-041-1105 - Requirements for Prescriptions
(1) Prescriptions,
prescription refills, and drug orders must be correctly dispensed in accordance
with the prescribing practitioner's authorization. When a prescription is
transmitted orally, both the receiving pharmacist's name or initials and the
name of the person transmitting must be noted on the prescription.
(2) Each pharmacy must document the following
information:
(a) The name of the patient for
whom or the owner of the animal and the species of the animal for which the
drug is dispensed;
(b) The full
name and, in the case of controlled substances, the address and the Drug
Enforcement Administration registration number of the practitioner or other
number as authorized under rules adopted by reference under rule OAR
855-080-0085;
(c) The name, strength, dosage forms of the
substance, quantity prescribed and, if different from the quantity prescribed,
the quantity dispensed;
(d) The
directions for use, if given by the practitioner; and
(e) The date of filling, and the total number
of refills authorized by the prescribing practitioner.
(3) In accordance with ORS
689.515(3), a
practitioner may specify in writing, by a telephonic communication or by
electronic transmission that there may be no substitution for the specified
brand name drug in a prescription.
(a) For a
hard copy prescription issued in writing or a prescription orally communicated
over the telephone, instruction may use any one of the following phrases or
notations:
(A) No substitution;
(B) N.S.;
(C) Brand medically necessary;
(D) Brand necessary;
(E) Medically necessary;
(F) D.A.W. (Dispense As Written);
or
(G) Words with similar
meaning.
(b) For an
electronically transmitted prescription, the prescriber or prescriber's agent
shall clearly indicate substitution instructions by way of the text (without
quotes) "brand medically necessary" or words with similar meaning, in the
electronic prescription drug order, as well as all relevant electronic
indicators sent as part of the electronic prescription transmission.
(c) Such instructions shall not be default
values on the prescription.
(4) A pharmacy or pharmacist filling a
prescription or order for a biological product may not substitute a biosimilar
product for the prescribed biological product unless:
(a) The biosimilar product has been
determined by the United States Food and Drug Administration to be
interchangeable with the prescribed biological product;
(b) The prescribing practitioner has not
designated on the prescription that substitution is prohibited;
(c) The patient for whom the biological
product is prescribed is informed of the substitution prior to dispensing the
biosimilar product;
(d) The
pharmacy or pharmacist provides written, electronic or telephonic notification
of the substitution to the prescribing practitioner or the prescribing
practitioner's staff within three (3) business days of dispensing the
biosimilar product; and
(e) The
pharmacy or pharmacist retains a record of the substitution for a period of not
less than three (3) years.
(5) Upon written request and for good cause,
the Board may waive any of the requirements of this rule. A waiver granted
under this section shall only be effective when it is issued by the Board in
writing.
Notes
Statutory/Other Authority: ORS 689.205 & 2013 OL Ch. 342
Statutes/Other Implemented: ORS 689.505, 689.515 & 2013 OL Ch. 342
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.